And when chatbots get stressed out, they are less likely to be useful in therapeutic settings with people. The bot’s anxiety ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...
Two Floridian icons, Lilly Pulitzer and Disney, have just teamed up for their biggest collaboration yet, and it’s exactly ...
The S&P 500 (SNPINDEX: ^GSPC) is cooling off after rip-roaring gains of over 20% in both 2023 and 2024. The Nasdaq Composite ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...
People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Amy Webb, CEO of the Future Today Strategy Group, reflects on the death of privacy and the lack of preparation for the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback